This stock is a great choice for cautious and aggressive investors.

If approved, gene therapies could fill gaps in patient care left by CFTR modulators, notes GD Healthcare analyst, Vinie Varkey.

People with cystic fibrosis (CF) are uniquely vulnerable to the flu wave currently ripping through the UK, a clinical ...

A H3N2 virus - dubbed 'super flu' - is sweeping hospitals in England - and people with one health condition may be more at ...

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5,with follow-up through 1 year at dose selected for Phase 2 Durable ...

Cystic fibrosis, a genetic disorder, affects lungs and other organs. It causes thick mucus buildup. Researchers have identified over 2,000 gene mutations. New treatments called CFTR modulators are now ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, Vertex's revenue soared 11% to more than $3 billion -- that's with net ...

The NICE-Wide Prioritisation Board met on 03 November 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Although ETI and other CFTR modulators have transformed the management of CF by targeting the defective CFTR protein, their long-term impact on systemic inflammation has not been well understood. This ...